New Drugs and Regulation · eu
A New Once-Daily GLP-1 Option: Lilly’s Orforglipron Recommended for European Approval
Foundayo targets both weight management and type 2 diabetes and can be taken with or without food. Clinical studies support its weight-loss and blood glucose-lowering effects, but formal EU approval and national reimbursement processes remain to be completed.
For people who need long-term weight and blood glucose control, how a medicine fits into daily life is also part of treatment. Lilly’s oral GLP-1 drug orforglipron, marketed as Foundayo, has now moved another step closer to the EU market: on October 15, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use adopted a positive opinion recommending it for weight management and type 2 diabetes in adults. The final marketing authorization decision remains with the European Commission.
Foundayo is a once-daily tablet that can be taken at any time of day, with or without food. Its active ingredient is a non-peptide small molecule that activates GLP-1 receptors to reduce appetite, increase feelings of fullness, and stimulate insulin release when blood glucose is elevated. This makes it another option alongside injectable and existing oral GLP-1 medicines, but convenience alone does not demonstrate better efficacy or more consistent adherence.
The recommended weight-management indication covers adults with a body mass index (BMI) of at least 30, or a BMI of 27 to less than 30 with at least one weight-related comorbidity, such as hypertension or type 2 diabetes. The diabetes indication is for adults with inadequately controlled blood glucose. It may be used alone when metformin is unsuitable, or in combination with other diabetes medicines. Both uses require a healthy diet and physical activity.
The weight-loss evidence comes from two studies involving a total of 4,740 adults, covering populations with and without type 2 diabetes. According to the EMA’s summary, after 72 weeks of treatment, body weight decreased by approximately 5% to 11% in the Foundayo groups, depending on dose, compared with approximately 2% to 2.5% in the placebo groups. These figures reflect results across different doses and study conditions; not every user will achieve the same degree of weight loss.
For blood glucose control, four main studies involving a total of 3,765 adults measured efficacy through changes in glycated hemoglobin (HbA1c). Foundayo reduced HbA1c by approximately 1.2 to 1.9 percentage points. Comparators across the studies included placebo, dapagliflozin, and oral semaglutide. Because background treatments, doses, and comparators differed across the trials, this range of reductions alone cannot be treated as an efficacy ranking against all existing medicines.
Beyond efficacy, tolerability will also affect long-term use. Both the EMA and Deutsches Ärzteblatt noted that common adverse reactions include nausea, vomiting, and diarrhea, particularly during gradual dose increases, with their frequency declining afterward. Treatment therefore starts at a low dose and is then adjusted according to treatment response and tolerability. An oral formulation does not mean these gastrointestinal reactions can be avoided.
Further steps remain between the regulatory recommendation and patients actually obtaining the medicine. The European Commission must first make a marketing authorization decision, after which pricing and reimbursement will be handled by individual member states. This development adds another potential oral treatment for weight and blood glucose management. How many patients may benefit will still depend on the terms of formal approval, treatment tolerability, and access within each country’s healthcare system.